New COVID-19 vaccine shows promise in large trial

NCT ID NCT05212948

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial tested a new COVID-19 vaccine called S-268019-b in nearly 10,000 adults. Participants received either the vaccine or a placebo to see if it could prevent COVID-19. The study looked at how many people got sick after vaccination and checked for safety and immune response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

S-268019-b vaccine

What this could lead to

If successful, this vaccine could help prevent COVID-19, reducing infections and severe illness.

What could go wrong

This trial is completed, but results may not apply to new variants. As with any vaccine, there is a small risk of side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SARS COV-2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

COVID-19 prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Buon Ma Thuot City Medical Center

    Buon Ma Thuot, Dak Lak, Vietnam